3-Alkoxy Thiophene Carboxamide Derivatives for Peripheral CB1 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CB1 cannabinoid receptor antagonists have limitations in specificity and brain penetration, which affects their therapeutic efficacy and side effect profiles.
Innovation Solution
Development of 3-alkoxy-4,5-diarylthiophene-2-carboxamide derivatives with specific substituents that exhibit antagonistic properties towards peripheral CB1 receptors while minimizing brain penetration, characterized by specific structural formulas and synthesis processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current CB1 cannabinoid receptor antagonists are used, then CB1 receptor antagonism is achieved, but brain penetration is excessive leading to unwanted side effects
Solution Approach 1:
The patent applies local quality by introducing a specific 3-alkoxy substituent at position 3 of the thiophene ring, creating a localized structural modification that differentially affects brain penetration versus peripheral receptor binding. This local structural change enables the compound to maintain therapeutic efficacy at peripheral CB1 receptors while reducing unwanted brain penetration and associated side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying the alkoxy chain length (R2 = (C1-C4)alkyl) and substituent types at position 3 of the thiophene ring to optimize the balance between brain penetration and peripheral selectivity. By adjusting these molecular parameters, the compounds achieve reduced brain penetration while maintaining adequate peripheral CB1 receptor antagonism for therapeutic effect.
2Adaptability or versatility
If CB1 receptor antagonists with high brain penetration are used, then central therapeutic effects are achieved, but peripheral selectivity is lost
Solution Approach 1:
The introduction of the 3-alkoxy substituent creates a local structural feature that selectively reduces brain penetration while preserving peripheral CB1 receptor binding affinity. This localized modification allows the compound to adapt to peripheral targets while being excluded from central nervous system tissue, achieving peripheral selectivity without sacrificing overall therapeutic capability.
3Measurement precision
If existing CB1 antagonist structures are used, then broad CB1 activity is achieved, but specificity for peripheral receptors is insufficient
Solution Approach 1:
The patent achieves enhanced receptor binding specificity through a focused local modification at position 3 of the thiophene ring. Rather than making extensive changes throughout the molecule, the 3-alkoxy substituent provides the critical specificity enhancement needed for peripheral CB1 receptor selectivity, maintaining reasonable molecular complexity while improving binding precision.
Data Source
AI summary
The invention relates to compounds of the formula (I), where: -R1 is: a -NR5R6 group; an unsubstituted or substituted phenyl; -R2 is: a (C1-C4)alkyl; an -X-R7 group; -R3 and R4 each are independently a substituted phenyl; -R5 is a hydrogen atom or a (C1-C4)alkyl; -R6 is an unsubstituted or substituted (C1-C4)alkyl; or R5 and R6 together with the nitrogen atom to which they are bonded constitute an unsubstituted or substituted heterocyclic compound; -X is a (C1-C5)alkylene; -R7 is an -OR8 group, a -NR9R10 group, an -SO2-(C1-C4)alkyl group; -R8 is a hydrogen atom or a (C1-C4)alkyl; -R9 is a hydrogen atom or a (C1-C4)alkyl; -R10 is a hydrogen atom, a -COR11 group, an -SO2R11 group or a -CO(CH2)mOH group; -R11 is an unsubstituted or substituted (C1-C4)alkyl; -m is 1, 2 or 3. The invention also relates to methods for preparing same and to the therapeutic use thereof.